Mesa Labs Q2 Operating Income Jumps 78% to $8.4M; Board Authorizes New $40M Buyback
MLAB sits 76% above its 52-week low of $69.51.
Summary
Mesa Labs grew Q2 revenue 2.6% to $62.3M while operating income jumped 77.6% to $8.4M, and the board authorized a new $40.0M share repurchase program. Clinical Genomics weakness will trigger a goodwill impairment test in Q3 FY2027.
Key Events · Earnings and Guidance · MLAB
-
Q2 Operating Income Up 78%
Revenue rose 2.6% to $62.3M and operating income jumped 77.6% to $8.4M; diluted EPS was $0.75 versus $0.45 a year earlier.
-
Six-Month Operating Income Nearly Doubles
First-half operating income reached $15.4M, up 98.0% from $7.8M, on gross margin of 64.4% versus 61.7%.
-
New $40M Buyback Authorized
On November 4, 2026 the board terminated the 2005 repurchase program and authorized up to $40.0M of buybacks through December 31, 2028, funded from cash and operations.
-
Debt Paydown Continues
The revolver fell to $67.3M from $84.5M at March 31, 2026, with $57.8M available; an additional $5.0M was repaid after quarter-end.
Analysis · MLAB · Industrial Applications And Services
Mesa's fiscal Q2 delivered real operating leverage: revenue rose 2.6% to $62.3M while operating income jumped 77.6% to $8.4M and diluted EPS climbed to $0.75 from $0.45, lifting six-month operating income 98.0% to $15.4M. Gross margin improved on lower contract labor and tariff costs, and the company kept paying down debt, cutting the revolver to $67.3M from $84.5M at fiscal year-end. Against that backdrop the board replaced a dormant 2005 repurchase authorization with a new $40.0M program through December 2028, and a September credit amendment now permits buybacks. The offsetting risk is Clinical Genomics: revenue fell 8.8% and management will run a quantitative goodwill and long-lived asset impairment test in Q3 FY2027 on $17.2M of goodwill plus $7.2M of intangibles, so a non-cash charge is possible.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLAB was trading at $122.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $715.3M. The 52-week trading range was $69.51 to $144.35. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.